Patents by Inventor Hamid R. Hoveyda

Hamid R. Hoveyda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190300478
    Abstract: The present invention is directed to novel compounds of formula (I) and their use in treating and or preventing metabolic diseases.
    Type: Application
    Filed: June 18, 2019
    Publication date: October 3, 2019
    Inventors: Hamid R. Hoveyda, Didier Schils, Ludivine Zoute, Julien Parcq
  • Patent number: 10358416
    Abstract: The present invention is directed to a process for the preparation of aryl-carbonyl-pyrrolidine carboxylic acid derivative compounds which are useful in treating metabolic diseases, said process consisting of coupling a pyrrolidine ester compound with an aryl carboxylic acid derivative, followed by alkaline or acidic treatment, hydrogenolysis or treatment with a fluoride of the obtained intermediate, to afford novel aryl-carbonyl-pyrrolidine carboxylic acid derivative compounds.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: July 23, 2019
    Assignee: Epics Therapeutics
    Inventors: Hamid R. Hoveyda, Didier Schils, Ludivine Zoute, Julien Parcq
  • Publication number: 20190023711
    Abstract: The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.
    Type: Application
    Filed: July 27, 2018
    Publication date: January 24, 2019
    Inventors: Hamid R. Hoveyda, Guillaume Dutheuil, Graeme Lovat Fraser, Marie-Odile Roy, Mohamed El Bousmaqui, Frederic Batt
  • Publication number: 20180297944
    Abstract: The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.
    Type: Application
    Filed: June 20, 2018
    Publication date: October 18, 2018
    Inventors: Hamid R. Hoveyda, Didier Schils, Ludivine Zoute, Julien Parcq
  • Patent number: 10065960
    Abstract: The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: September 4, 2018
    Assignee: Ogeda SA
    Inventors: Hamid R. Hoveyda, Marie-Odile Roy, Graeme L. Fraser, Guillaume Dutheuil
  • Patent number: 10065961
    Abstract: The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: September 4, 2018
    Assignee: Ogeda SA.
    Inventors: Hamid R. Hoveyda, Guillaume Dutheuil, Graeme L. Fraser, Marie-Odile Roy, Mohamed E. Bousmaqui, Frederic Batt
  • Publication number: 20180194772
    Abstract: The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.
    Type: Application
    Filed: February 27, 2018
    Publication date: July 12, 2018
    Inventors: Hamid R. Hoveyda, Marie-Odile Roy, Graeme Lovat Fraser, Guillaume Dutheuil
  • Patent number: 10017468
    Abstract: The present invention is directed to a process for the preparation of aryl-pyrrolidine carboxylic acid derivative compounds which are useful in treating metabolic diseases, said process consisting of coupling an aryl-pyrrolidine compound with an aryl carboxylic acid compound followed by alkaline or acidic treatment, hydrogenolysis or treatment with a fluoride of the ester intermediate to afford novel aryl-pyrrolidine carboxylic acid derivative compounds.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: July 10, 2018
    Assignee: Ogeda SA
    Inventors: Hamid R. Hoveyda, Didier Schils, Ludivine Zoute, Julien Parcq
  • Publication number: 20180110824
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Application
    Filed: October 21, 2016
    Publication date: April 26, 2018
    Inventors: Hamid R. Hoveyda, Graeme L. Fraser, Mark Peterson
  • Patent number: 9926325
    Abstract: The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: March 27, 2018
    Assignee: Ogeda SA
    Inventors: Hamid R. Hoveyda, Marie-Odile Roy, Graeme L. Fraser, Guillaume Dutheuil
  • Publication number: 20170283376
    Abstract: The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 5, 2017
    Inventors: Hamid R. Hoveyda, Didier Schils, Ludivine Zoute, Julien Parcq
  • Patent number: 9695120
    Abstract: The present invention is directed to novel pyrrolidine carboxylic acid derivatives, pharmaceutical compositions, and their use in treating and/or preventing metabolic diseases as agonists of g-protein coupled receptor 43.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: July 4, 2017
    Assignee: Ogeda SA
    Inventors: Hamid R. Hoveyda, Didier Schils, Ludivine Zoute, Julien Parcq
  • Patent number: 9475814
    Abstract: The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: October 25, 2016
    Assignee: Euroscreen S.A.
    Inventors: Hamid R. Hoveyda, Guillaume Dutheuil, Graeme L. Fraser, Marie-Odile Roy, Mohamed El Bousmaqui, Frederic Batt
  • Publication number: 20150315199
    Abstract: The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.
    Type: Application
    Filed: July 14, 2015
    Publication date: November 5, 2015
    Inventors: Hamid R. Hoveyda, Marie-Odile Roy, Graeme L. Fraser, Guillaume Dutheuil
  • Publication number: 20140371218
    Abstract: The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 18, 2014
    Inventors: Hamid R. Hoveyda, Marie-Odile Roy, Graeme L. Fraser, Guillaume Dutheuil
  • Patent number: 8871761
    Abstract: The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: October 28, 2014
    Assignee: Euroscreen S.A.
    Inventors: Hamid R. Hoveyda, Marie-Odile Roy, Graeme Lovat Fraser, Guillaume Dutheuil
  • Publication number: 20140275097
    Abstract: The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.
    Type: Application
    Filed: October 3, 2012
    Publication date: September 18, 2014
    Inventors: Hamid R. Hoveyda, Guillaume Dutheuil, Graeme L. Fraser, Marie-Odile Roy, Mohamed El Bousmaqui, Frederic Batt
  • Patent number: 8557765
    Abstract: Novel spatially-defined macrocyclic compounds incorporating peptide bond surrogates are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: October 15, 2013
    Assignee: Tranzyme Pharma Inc.
    Inventors: Pierre Deslongchamps, Yves Dory, Luc Ouellet, Gérald Villeneuve, Mahesh Ramaseshan, Daniel Fortin, Mark L. Peterson, Hamid R. Hoveyda, Sylvie Beaubien, Éric Marsault, Graeme L. Fraser
  • Patent number: 8497242
    Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: July 30, 2013
    Assignee: Tranzyme Pharma Inc.
    Inventors: Éric Marsault, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
  • Patent number: 8450268
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: May 28, 2013
    Assignee: Tranzyme Pharma Inc.
    Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson